The effects of 1% lidocaine as a diluent on the pharmacokinetics and tolerance of ceftriaxone administered intramuscularly were investigated in 12 adult volunteers. Each subject received two 0.5-g doses of ceftriaxone (one in water and the other in 1% lidocaine) at least 1 week apart in a randomized crossover fashion. Plasma and urine samples were collected serially and assayed for ceftriaxone content by high-performance liquid chromatography. The mean peak plasma concentration, time to attain the peak, area under the plasma curve from time zero to infinity, and elimination half-life were 45 ,ug/ml, 2.5 h, 578 ,ug h/ml, and 7.1 h, respectively, after intramuscular administration of ceftriaxone in water diluent. The corresponding mean values in 1% lidocaine diluent were 42 ,g/ml, 3 h, 577 ,ug h/ml, and 7.0 h. The pharmacokinetic data suggested that 1% lidocaine does not alter either the elimination parameters or the bioavailability of intramuscularly administered ceftriaxone. The intensity and frequency of pain at the injection site were reduced considerably by the coadministered lidocaine.
Ceftriaxone (Ro 13-9904), an experimental parenteral cephalosporin, displays a high order of activity against gram-positive and gram-negative bacteria and enhanced stability against various types of P-lactamases (6) . The pharmacokinetic characteristics of ceftriaxone have been defined in normal healthy subjects after administration of single and multiple intravenous (i.v.) doses (5, 6, 9, 11, 12) . The elimination half-life of ceftriaxone ranged from 5.9 to 8.8 h, considerably longer than the half-life range (0.6 to 3.0 h) reported for other experimental and marketed cephalosporins (6) . Intramuscular (i.m.) administration of cephalosporins such as cefoxitin and cefamandole causes pain at the injection site. This can be reduced greatly by administering these cephalosporins in combination with a local anesthetic (2) . In a preliminary study with six healthy volunteers, a single i.m. dose of 0.5 g of ceftriaxone dissolved in water produced moderate to severe pain (unpublished data). This observation led to the present study, in which two solutions of ceftriaxone (one in water and the other in 1% lidocaine diluent) were administered i.m. to 12 normal, healthy subjects in a randomized, crossover design. The influences of these diluents on the pharmacokinetics and pain parameters of ceftriaxone were compared.
MATERIALS AND METHODS
Subjects. Twelve healthy adult subjects, 6 males and 6 females, ranging in age from 28 to 47 years (mean, 38 years) and in body weight from 51.6 to 86.8 kg (mean, 66.7 kg) participated in this study. All subjects gave written informed consent. Prestudy physical examination, a recent X ray, electrocardiogram, blood cell count, fasting blood sugar, blood urea nitrogen, bilirubin, creatinine, creatine phosphokinase (CPK), serum glutamic oxalacetic transaminase, serum glutamic pyruvic transaminase, alkaline phosphatase, drug abuse screen, and urinalysis were normal for each subject. In first-time volunteers, a glucose-6-phosphate dehydrogenase screening test and hemoglobin electrophoresis were performed.
Study design. The drug solutions used in this study were prepared by reconstituting ceftriaxone sodium equivalent to 0.5 g of anhydrous free acid in 2 ml of water or 2 ml of a 1% lidocaine solution. These solutions were injected i.m. in the lateral thigh of each subject, using a single-blind, randomized crossover design with a minimum 1-week interval separating drug deliveries. Subjects fasted overnight before the i.m. doses and for 4 h thereafter. To facilitate blood sampling, an i.v. catheter with a heparin lock was inserted in the antecubital vein before dosing and remained in place for about 8 h. Subsequent blood samples were obtained by venipuncture.
Specimen collection. Blood samples were collected into tubes containing heparin before the administration of ceftriaxone and 5, 10, 20, and 40 min and 1, 1.5, 2, 3, ANTIMICROB. AGENTS CHEMOTHER. Stscal analysis. The statistical analysis was performed by using a two-tailed paired t-test.
RESULTS
Effect of 1% lidocaine on the pharmacokinetics of ceftriaxone. The concentrations of ceftriaxone in plasma and urine at various times after i.m. administration are shown in Tables 1 and 2 , respectively, and the corresponding pharmacokinetic parameters are shown in Table 3 . Comparisons of 1% lidocaine and water diluent data indicated that the coadministered lidocaine did not alter the following distribution and elimination parameters of ceftriaxone (Table 3) : (i) apparent volume of distribution, Vd; (ii) elimination rate constant, 3; (iii) plasma clearance, Clp; (iv) renal clearance, Clr; (v) fraction of dose excreted unchanged in urine,fe; and (vi) cumulative renal excretion proffle (Fig. 1) . The following bioavailability parameters of ceftriaxone (Table 3) were also not altered significantly by lidocaine: (i) maximum plasma concentration, C,n,; (ii) maximum plasma concentration-time, t.x; and (iii) AUC. However, the following absorption rate parameters of ceftriaxone were reduced slightly, but statistically significantly, by lidocaine: (i) plasma ceftriaxone concentrations at 10, 20, 40, and 60 min after administration of ceftriaxone in 1% lidocaine diluent were lower than the corresponding concentrations for water diluent (Table 1) ; (ii) the absorption rate constant, k0, for 1% lidocaine diluent (0.94 h1) was smaller than that (1.34 h1) for water diluent (Table 3) ; and (iii) absorption values, A/Vd, at 10, 20, 40, and 60 min postdose for 1% lidocaine diluent were smaller than the corresponding values for water diluent (Fig. 2) . Although mean maximum plasma concentrations were achieved Table 4 . There was considerable intersubject variability in the pain intensity score at each recording time. The pain at the injection site was generally more frequent and more marked when the drug was administered in water diluent. The pain intensity score was statistically significantly lowered by 1% lidocaine at 0, 0.25, and 0.5 h postdose. The mean (± standard deviation) areas under the pain intensity score versus time plots were 50.9 (± 55.3) mm-h for water diluent and 11.9 (± 16.1) mm-h for 1% lidocaine diluent; this difference was statistically significant.
i.m. administration of ceftriaxone caused a considerable elevation in the serum CPK levels ( Table 5 ). The maximum elevation was generally seen at 24 h after i.m. injection (10 of 14 cases). The elevation in the serum CPK level was found in a greater number of subjects and to a greater extent when the drug was administered in water diluent ( Table 5 ). The serum CPK levels returned to normal range in all subjects upon follow-up (3 to 4 weeks).
A slight increase in leukocytes was seen in one subject, and a slight increase in serum glutamic oxalacetic transaminase was seen in another subject. Both increases were transient and apparently not drug related. DISCUSSION The pharmacokinetic parameters of ceftriaxone observed in the present study agreed well with those determined in a previous 30-min i.v. infusion study (5) at an equivalent dose ( Table  6 ). The mean AUC values estimated in the present study are equivalent to that estimated after i.v. administration of a 0.5-g dose in the previous study (5; Table 6 ). This indicates that The effects of lidocaine on the pharmacokinetic and tolerance parameters of ceftriaxone are consistent with those reported for cefoxitin by Sonneville et al. (10) and for cefamandole by Foster et al. (2) . In both of these studies, lidocaine (0.5 to 1%) reduced the pain associated with i.m. injections without altering significantly the pharmacokinetic parameters of these cephalosporins.
Plasma samples were not assayed for lidocaine in the present study. On the average, i.m. injection of 200-to 300-mg doses of lidocaine results in peak plasma levels of 1 to 3 ,ug/ml between 10 and 120 min postdose (1). Therefore, peak plasma lidocaine concentrations of less than 0.3 ,ug/ml could be expected from the 20-mg i.m. dose of lidocaine in the present study. These concentrations are considerably lower 21, 1982 on September 26, 2017 by guest http://aac.asm.org/ Downloaded from than those (1.5 to 4 ,g/ml) required to elicit a systemic antiarrhythmic effect (8) .
Serum CPK levels are generally elevated after i.m. injection because of the release of the enzyme from muscle cells that are injured by the physical trauma of injection (3) . Elevations in serum CPK levels tend to be greater when large volumes are injected, when the pH tonicity of the injected solution is far from the physiological range, or when the solution is intrinsically irritating. In the present study, elevations of serum CPK levels were more frequent and greater when drug was injected in water diluent than in 1% lidocaine. The reasons for these differences are not readily apparent.
